Key result
Platelet proteomics identifies promising new biomarkers and therapeutic targets for atherothrombotic events.
Why the study?
Platelet activity is regulated primarily by post-translational modifications, making proteomic techniques the most suitable tool to characterize the molecular mechanisms in platelet pathophysiology and atherothrombosis.
Platelet proteomics offers insights into atherothrombotic events and potential biomarkers, though clinical translation is currently limited by methodological variability.
Requires standardization before clinical translation; extends mechanistic insights into platelet reactivity in atherothrombosis.
INTRODUCTION: Abnormalities in the physiological processes of platelet activation can lead to the formation of unwanted blood clots and the onset of cardiovascular diseases. Due to their anucleated nature, platelet activity is regulated primarily by post-translational modifications in receptors and their associated signaling pathways; consequently, proteomic techniques are the most suitable tool for the study and characterization of the molecular mechanisms involved in platelet pathophysiology. AREAS COVERED: Following a comprehensive search in PubMed, this review analyzes the main contributions of proteomics technologies to platelet research and summarizes the most relevant proteomic-derived findings in the field of platelet biology to atherosclerosis progression and cardiovascular diseases (CVD). EXPERT OPINION: Platelet proteomics has significantly contributed to increase our understanding of atherothrombotic events and related CVD, and to identify promising candidates for new biomarkers and therapeutic targets. However, clinical translation remains limited due to methodological variability, insufficient standardization and the need for large-scale validation studies. Future progress will depend on consistent workflows, multidisciplinary approaches and the integration of proteomics with complementary omics and advanced bioinformatic technologies. Together, these advances are expected to improve patient characterization, therapeutic monitoring and the identification of novel biomarkers and drug targets with future clinical relevance in CVD assistance.
No takes yet. Share an insight, caveat, or question.
Troitiño et al. (2026) conducted a review in Atherosclerosis and cardiovascular diseases. Platelet proteomics was evaluated. Platelet proteomics has significantly contributed to understanding atherothrombotic events and identifying promising candidates for new biomarkers and therapeutic targets.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: